Women May Have Lower Risk for Chronic Kidney Disease Progression
A recent study has revealed women have a lower risk of chronic kidney disease (CKD) progression and death than men, but men have a higher likelihood of progression to end-stage renal disease (ESRD). Researchers noted that the prevalence of CKD is higher among women, while men have a 50 percent
higher lifetime risk of developing ESRD. The findings suggest that, compared to men, women could have a slower decline in kidney function or they’re more likely to die before progressing to ESRD.
Source: Nephrology News & Issues
Patients with End-Stage Kidney Disease Experience Barriers to Exercise
Researchers have found that patients with end-stage kidney disease want to exercise to improve quality of life, but often experience barriers like fatigue and weakness. The study discovered activity levels between modalities — peritoneal dialysis or hemodialysis — were similar, but varied among age groups with younger patients reporting more activity than older patients. Patients reported they wanted to have improved energy and strength from exercise and peritoneal dialysis patients also reported a desire for improved sleep.
Source: Clinical Journal of American Society of Nephrology
Vitamin D Therapy Boosts Hemodialysis Survival
New research suggests active vitamin D therapy improves survival among hemodialysis patients because it may decrease secondary vitamin D deficiency, which is considered partly to blame for excess mortality in hemodialysis along with hyperparathyroidism. Researchers found there was no excess risk for death in patients receiving high doses of the vitamin and recommend prescribing the therapy unless contraindicated.
Source: Renal & Urology News
Study to Begin on KidneyIntelX, New Diagnostic Tool for Tracking Chronic Kidney Disease Progression
The tool uses artificial intelligence to diagnose and improve clinical management of type 2 diabetes and those of African ancestry with rapidly progressing kidney disease. According to Nephrology News & Issues: “KidneyIntelX applies machine learning algorithms to assess the combination of predictive blood-based biomarkers and other genomic information in combination with information from electronic health records to help predict disease progression and drug/therapy response in individual patients.”
Source: Nephrology News & Issues
Statins May Improve Erythropoietin-Stimulating Agent (ESA) Response in Pre-Dialysis Patients
Researchers have found using statin therapy in pre-dialysis patients with chronic kidney disease may reduce hyporesponsiveness to ESA. Long-term statin use was associated with 85 percent lower odds of hyporesponsiveness.
Source: Renal & Urology News
